Relief Therapeutics Holding (XSWX:RLF) Interest Expense : CHF0.44 Mil (TTM As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Relief Therapeutics Holding Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Relief Therapeutics Holding's interest expense for the six months ended in Jun. 2023 was CHF -0.18 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was CHF0.44 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Relief Therapeutics Holding's Operating Income for the six months ended in Jun. 2023 was CHF -11.56 Mil. Relief Therapeutics Holding's Interest Expense for the six months ended in Jun. 2023 was CHF -0.18 Mil. Relief Therapeutics Holding did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Relief Therapeutics Holding Interest Expense Historical Data

The historical data trend for Relief Therapeutics Holding's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Interest Expense Chart

Relief Therapeutics Holding Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-0.14

-0.13

-0.10

-0.19

-0.16

Relief Therapeutics Holding Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Interest Expense	Get a 7-Day Free Trial															-0.06	-0.13	-0.78	0.63	-0.18

Relief Therapeutics Holding Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.44 Mil.

Relief Therapeutics Holding (XSWX:RLF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Relief Therapeutics Holding's Interest Expense for the six months ended in Jun. 2023 was CHF-0.18 Mil. Its Operating Income for the six months ended in Jun. 2023 was CHF-11.56 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2023 was CHF2.35 Mil.

Relief Therapeutics Holding's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Relief Therapeutics Holding did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Relief Therapeutics Holding (XSWX:RLF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (XSWX:RLF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFTF:USA RLFz:UK

Address

Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (XSWX:RLF) Headlines

No Headlines